Technical Analysis for ABUS - Arbutus Biopharma Corporation
|Grade||Last Price||% Change||$ Change|
ABUS closed up 5.26 percent on Friday, January 13, 2017, on 89 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Trend Table & Recent Alerts
|Weak or Absent||Down||Up||Up|
|See historical ABUS trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 13||Stochastic Reached Overbought||Other||0.00%|
|Jan 12||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||5.26%|
|Jan 12||Stochastic Sell Signal||Bearish||5.26%|
|Jan 12||NR7-2||Range Contraction||5.26%|
|Jan 12||NR7||Range Contraction||5.26%|
|Jan 11||NR7||Range Contraction||5.26%|
|Jan 11||50 DMA Support||Bullish||5.26%|
|Jan 10||Stochastic Reached Overbought||Other||5.26%|
|Jan 9||Expansion Pivot Buy Setup||Bullish Swing Setup||1.69%|
|Jan 9||Crossed Above 50 DMA||Bullish||1.69%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The companys products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ABUS news...
|52 Week High||5.48|
|52 Week Low||2.35|
|200-Day Moving Average||3.65|
|50-Day Moving Average||2.77|
|20-Day Moving Average||2.66|
|10-Day Moving Average||2.74|
|Average True Range||0.18|
|Chandelier Exit (Long, 3 ATRs)||2.47|
|Chandelier Exit (Short, 3 ATRs)||2.89|
|Upper Bollinger Band||2.99|
|Lower Bollinger Band||2.33|
|Percent B (%b)||1.02|